Ganetespib/Docetaxel combo improves OS in pre specified pops
Dr Suresh Ramalingam at targetedhcdotcom 7/24/13 on HSP90i with Ganetespib.
"An extension phase of GALAXY-1, focusing on biomarker analysis, recently completed accrual, with results expected to be reported later this year. In addition, the phase III GALAXY-2 trial will compare second-line ganetespib plus docetaxel versus docetaxel alone in advanced lung cancer patients with adenocarcinoma histology and will only enroll patients who are more than 6 months past a diagnosis of advanced disease. The target enrollment is 500 patients, and the primary endpoint is overall survival."
I'm with this guy. I think SNTA has powered this extension cohort to unquestionably tease out a statsig OS signal in adv lung cancer populations with histologic adenocarcinoma.